Compare prices and buy Retatrutide + Tirzepatide Blend from 5 research peptide vendors - also called suppliers or sources. Updated daily.
A research blend combining retatrutide (a triple GLP-1 / GIP / glucagon receptor agonist) with tirzepatide (a dual GLP-1 / GIP agonist). Tirzepatide is FDA-approved as Mounjaro and Zepbound, while retatrutide remains investigational. No registered trial gives the two together, so the pairing is a market convention rather than a pharmacological one. Splits vary by vendor, and the blend is sold for research use only.
For research purposes only. Not medical advice.
The retatrutide + tirzepatide blend puts two Eli Lilly peptides in one vial. Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide, Lilly's LY3437943, activates the glucagon, GIP and GLP-1 receptors. Each has its own page for mechanism, trials, approvals, compounding history and vendor codes, and both sit in the GLP agonist and weight loss category.
The blend is a mixture, so it has no CAS number of its own, and the names it is sold under are vendor branding that no pharmacopeia recognizes. It has no standard split either. In-stock listings that state a split on a public page in October 2026 range from equal parts of each peptide to two parts tirzepatide per part retatrutide by mass.
Tirzepatide's FDA label describes it as a GIP receptor and GLP-1 receptor agonist that selectively binds to and activates both. Lilly's discovery paper describes retatrutide as a triple agonist peptide at the glucagon, GIP and GLP-1 receptors (Coskun and colleagues, Cell Metabolism, 2022). Both of tirzepatide's targets are therefore among retatrutide's.
In a vial holding both, the GLP-1 and GIP receptors are targets of two molecules and the glucagon receptor is the target of one. Tirzepatide adds a second agonist at receptors retatrutide already reaches, and no receptor that retatrutide does not. That overlap describes the two molecules. It is not evidence about the mixture, which no registered trial has tested.
A search of ClinicalTrials.gov on October 21, 2026 found two registered studies that include both drugs. Both are Phase 3 trials sponsored by Eli Lilly, and both give the drugs in separate arms.
No arm of either study gives retatrutide and tirzepatide together, and none of retatrutide's other registered studies includes tirzepatide, so the pairing in these vials is a market convention rather than a pharmacological one.
Each component has its own regulatory story. Tirzepatide is the active ingredient of Eli Lilly's FDA-approved Mounjaro and Zepbound, and the tirzepatide page covers its approvals and why the compounding bulks lists do not set its status. Retatrutide holds no FDA approval and remains investigational, and the retatrutide page covers Lilly's filing plans, the FDA's classification of the molecule and why it cannot be compounded.
As of October 21, 2026, Drugs@FDA lists no product containing retatrutide, and every product it lists containing tirzepatide has tirzepatide as its only active ingredient. No approved product combines the two.
Vendor titles join a code for each component, built on the generational GLP-N convention in which 2 marks tirzepatide and 3 marks retatrutide.
The letter matters because a bare GLP-2 can mean tirzepatide or teduglutide depending on the seller, as the category page explains. Only a certificate of analysis that identifies and quantifies each peptide shows what a vial holds.
PeptideScouter records a blend's size as the vial's total peptide content, and the blend is sold as vials, so its listings carry a per-milligram price. Because splits differ, that figure compares only with an average of the two single-compound prices weighted by the listing's own split, and vials with different splits are not like-for-like. The tesamorelin + ipamorelin page explains the general case.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
Two Eli Lilly peptides in one vial: tirzepatide, an agonist of the GIP and GLP-1 receptors, and retatrutide, an investigational agonist of the glucagon, GIP and GLP-1 receptors. The split varies by vendor. In-stock listings that state one on a public page in October 2026 range from equal parts to two parts tirzepatide per part retatrutide by mass, and PeptideScouter records the combined total as the vial size. The blend is a mixture with no CAS number of its own, and only a certificate of analysis that identifies and quantifies each peptide shows what a vial holds. Material sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
Not in a registered trial, as of October 21, 2026. ClinicalTrials.gov lists two Eli Lilly Phase 3 studies that include both drugs, and each gives them in separate arms. TRIUMPH-5 compares retatrutide with tirzepatide in adults with obesity, and SYNERGY-Outcomes, a master protocol in metabolic dysfunction-associated steatotic liver disease, tests each drug against placebo. No arm of either study gives the two drugs together.
Both of tirzepatide's. Tirzepatide's FDA label describes it as an agonist of the GIP and GLP-1 receptors, and Eli Lilly describes retatrutide as an agonist of the glucagon, GIP and GLP-1 receptors. In a vial holding both, the GLP-1 and GIP receptors are targets of two molecules and the glucagon receptor is the target of one, so tirzepatide adds no receptor that retatrutide does not already reach. This describes the two molecules, and no registered trial has tested the mixture.
No. Tirzepatide by itself is FDA-approved as Eli Lilly's Mounjaro and Zepbound, while retatrutide holds no FDA approval and remains investigational. As of October 21, 2026, Drugs@FDA lists no product containing retatrutide and no product combining it with tirzepatide. The blend sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
They follow the generational GLP-N convention, in which 2 marks tirzepatide and 3 marks retatrutide, with a letter such as T or R naming the compound. The letter matters because in scientific naming GLP-2 is a separate hormone whose analog, teduglutide, is an unrelated drug. In the GLP-2(T) + GLP-3(R) listing, the stated 40/20 split follows the order of the names, 40 mg tirzepatide and 20 mg retatrutide.
Retatrutide + Tirzepatide Blend is sold by 5 research peptide vendors indexed on PeptideScouter, with 7 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 5 indexed research peptide vendors currently have Retatrutide + Tirzepatide Blend in stock. Stock state is refreshed daily from each vendor's catalog.
Glacier Aminos currently lists Retatrutide + Tirzepatide Blend at $3.00/mg, the lowest listed price across 5 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.70/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 5 vendors listing Retatrutide + Tirzepatide Blend publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $3.00/mg listed to $2.70/mg at Glacier Aminos. Each vendor's code is shown beside its price in the table above.
Retatrutide + Tirzepatide Blend ranges from $3.00/mg to $5.00/mg across 7 listings from 5 research peptide vendors, normalized to USD per milligram and refreshed daily.
5 research peptide vendors currently list Retatrutide + Tirzepatide Blend on PeptideScouter. We track 7 listings across size and kit variants.
